Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi High Risk of Acute Exacerbation of Interstitial Lung Disease In Relapsed Small Cell Lung Cancer Treated With Amrubicin
*Corresponding Author:
Copyright: © 2018 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Lung cancer is the leading cause of death from cancer worldwide. Small cell lung cancer (SCLC) accounts for 15% to 20% of lung cancer. SCLC is characterized by a high rate of invasion and rapid cell proliferation. The SCLC also shows a high sensitivity to chemotherapy and radiotherapy; however, the duration of the response is relatively short. The standard chemotherapy regimen for SCLC patients is a combination of platinum and etoposide agents or platinum agents plus irinotecan, which is the most frequently used combination and gives a median survival period of approximately 9 to 12 months in clinical trials.
